drugset / Trial / NCT00106158

Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1

NCT00106158 ↗

Phase 1 Completed 9 enrolled Ludwig Institute for Cancer Research
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of repeated doses of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and describe the NY-ESO-1 specific-humoral and cellular immune response to immunization with CHP-NY-ESO-1 in patients with cancer expressing NY-ESO-1.

Timeline

Start
2004-06
Primary completion
—
Completion
2006-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject protein vaccination Vaccine — —

Indications